Picton Mahoney Asset Management Has $13.95 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Picton Mahoney Asset Management grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 50.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 633,149 shares of the company’s stock after purchasing an additional 213,041 shares during the quarter. Picton Mahoney Asset Management’s holdings in Teva Pharmaceutical Industries were worth $13,953,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in TEVA. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Janus Henderson Group PLC increased its position in shares of Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after buying an additional 4,732,374 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $58,243,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Teva Pharmaceutical Industries by 237.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock valued at $60,863,000 after buying an additional 2,376,668 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, March 7th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $16.38 on Friday. The stock has a 50-day moving average price of $18.28 and a two-hundred day moving average price of $18.30. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market cap of $18.57 billion, a PE ratio of -11.29, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.